Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.54 |
| ▸ | AKT2 | P31751 | 6/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5263137 | 0.94 | AKT1 (0.62) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5265616 | 0.94 | AKT1 (0.62) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5266214 | 0.93 | MAPK14 (0.54) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5263183 | 0.93 | AKT1 (0.49) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5262399 | 0.93 | AKT1 (0.49) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5261912 | 0.91 | AKT1 (0.47) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5263043 | 0.89 | AKT1 (0.48) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5261861 | 0.88 | AKT1 (0.45) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5261672 | 0.87 | AKT1 (0.44) | AKT1AKT2PTGS1PTGS2MAPK14 | |
| SCHEMBL5263158 | 0.85 | MAPK14 (0.45) | AKT1AKT2PTGS1PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660500-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER | S A L V A T LAB SA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189631-A1 | Substituted imidazopyrimidines for the prevention and treatment of cancer | BRCA1, CCNA1, DPYD | AKT1 3579/4885AKT2 3297/4885PTGS1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.